Market news

Halozyme Therapeutics (NASDAQ:HALO) has outperformed the market over the past 15 years by 8.16% on an annualized basis producing an average annual return of 21.6%. Currently, Halozyme Therapeutics has a market

Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

On September 17, Halozyme (NASDAQ:HALO) priced $1.3 billion of convertible senior notes due 2033, an offering that grew from an originally planned $1.05 billion as demand came in. The notes carry a 1.50% coupon and convert into stock at $139.84 a share, a 27.5% premium to the $109.68 closing price that day. Investors who like […]

Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on September 16 a proposed $1.05 billion offering of convertible senior notes due October 1, 2033. The plan includes an expected option for initial purchasers to buy another $150 million. The interest rate and initial conversion terms were to be determined at pricing. Halozyme Therapeutics, Inc. (NASDAQ:HALO) intends to use […]

Halozyme Therapeutics (HALO) plans to launch an offering of $1.05 billion of convertible senior note

Halozyme Therapeutics (HALO) heads into a busy investor calendar, with management scheduled to speak at three major healthcare and investment conferences in early and mid September 2026, putting the stock back under the spotlight. Despite a slight pullback with a 1-day share price return of 1.57% and a 7-day share price return of 1.90%, Halozyme Therapeutics has built strong momentum, with a 30-day share price return of 7.69% and a 90-day gain of 54.95% helping lift the year-to-date share...

Institutions have pushed Halozyme Therapeutics, Inc. (HALO) shares up 769% since March 2014.

Halozyme (NASDAQ:HALO) will participate in three healthcare investor conferences during September, giving management multiple opportunities to discuss its commercially validated ENHANZE platform and expanding portfolio of drug delivery technologies. Key Investor TakeawaysHalozyme (NASDAQ:HALO) management will participate in investor events hosted by Wells Fargo, Morgan Stanley and H.

Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Darren Snellgrove, Chief Financial Officer, are scheduled to participate and host investor meetings at the following investor conferences.

Halozyme Therapeutics is evolving into a diversified, high-margin royalty platform. Click here to find out why HALO stock is a Buy.

Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market.

Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Herbalife, Honda Motor, Marathon, Halozyme and Genworth have been highlighted in this Screen of The Week article.

Halozyme Therapeutics stock has delivered a strong share price run over the past few years, yet current valuation checks suggest the stock leans expensive on traditional market multiples and does not screen as a clear bargain overall. Over the past 3 years, Halozyme Therapeutics has returned about 151%, which puts extra focus on whether the current share price already bakes in much of the good news. The recent appointment of Dannielle Appelhans to the Board may support confidence in...

Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.

Halozyme stock jumps 36% in a month as strong ENHANZE-driven royalties and recently raised 2026 guidance boost investor confidence.

Detailed price information for Halozyme Therapeutic (HALO-Q) from The Globe and Mail including charting and trades.

Halozyme Therapeutics delivered a notably positive second quarter, as evidenced by the strong market reaction and management’s attribution of outperformance to surging royalty revenue and a wave of new collaboration agreements. CEO Helen Torley highlighted that the ENHANZE platform, now underpinning revenue from six different drugs, enabled a record 50% year-over-year royalty growth. The quarter also benefited from sizable milestone payments tied to newly signed licensing deals, with Torley emph

On July 20, Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Incyte Corporation (NASDAQ:INCY) announced a global collaboration and licensing deal to develop a subcutaneous formulation of Incyte’s INCA033989. The first-in-class monoclonal antibody targets mutant calreticulin (mutCALR)-expressing myeloproliferative neoplasms. By utilizing Halozyme’s proprietary ENHANZE drug delivery technology, INCY aims to create a more convenient dosing regimen for patients. […]

Motley Fool Press Release.

Halozyme Therapeutics (HALO) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Here is how Halozyme Therapeutics (HALO) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.

Detailed price information for Halozyme Therapeutic (HALO-Q) from The Globe and Mail including charting and trades.

Shares of biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) jumped 18.1% in the afternoon session after the company reported strong second-quarter earnings that surpassed analyst expectations and raised its full-year financial guidance.

Halozyme stock rocketed to a record high Friday as its newer Enhanze-tied products starting driving incremental growth.